Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417484 | 0.88 | ENPP1 (0.32) | METAP2METAP1ENPP1 | |
| SCHEMBL3044434 | 0.87 | METAP2 (0.35) | METAP2METAP1ENPP1HPRT1GRIN2B | |
| SCHEMBL235437 | 0.79 | CACNA1H (0.41) | METAP2METAP1ENPP1GRIN2B | |
| SCHEMBL6485 | 0.74 | METAP2 (0.42) | METAP2METAP1ENPP1GRIN2B | |
| SCHEMBL29208955 | 0.71 | METAP2 (0.42) | METAP2METAP1ENPP1 | |
| SCHEMBL30884953 | 0.71 | METAP2 (0.42) | METAP2METAP1ENPP1 | |
| SCHEMBL4955472 | 0.71 | METAP2 (0.42) | METAP2METAP1ENPP1 | |
| SCHEMBL9516035 | 0.71 | METAP2 (0.35) | METAP2METAP1ENPP1 | |
| SCHEMBL4957389 | 0.71 | METAP2 (0.44) | METAP2METAP1ENPP1GRIN2B | |
| SCHEMBL9936013 | 0.71 | METAP2 (0.44) | METAP2METAP1ENPP1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1933848-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | Innate Pharma (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | METAP2 2424/4885METAP1 2269/4885ENPP1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.